InnoCare Pharma Ltd.SSE: 688428

Notice on Convening the 2026 Annual General Meeting

Apr 25, 2026 · Issued by InnoCare Pharma Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 25, 2026

On 6ix: 6ix.com/news/notice-on-convening-the-2026-annual-general-meeting-2

Notice on Convening the 2026 Annual General Meeting

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

InnoCare Pharma Ltd. on 6ix

Earlier from InnoCare Pharma

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained ProfitabilityApr 23
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and SafetyApr 21
Announcement on Convening the Q1 2026 Performance BriefingApr 16
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual ProfitMar 25
Announcement on Convening the 2025 Annual Performance BriefingMar 18

Later from InnoCare Pharma

InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLEApr 28
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% ScaleMay 1
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in ChinaMay 6
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in ChinaMay 7
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF InhibitorMay 13

All InnoCare Pharma news releases

Follow InnoCare Pharma into a list and get an email when it puts out news.

Follow InnoCare Pharma